

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93797

Yuji HOYANO, et al.

Appln. No.: 10/572,515

Group Art Unit: 1614

Confirmation No.: 4754

Examiner: Bong-Sook Baek

Filed: March 17, 2006

For: CONCURRENT DRUGS

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A telephone interview was conducted with the Examiner concerning this application during the week of September 7, 2009.

The purpose of the interview was to question what the Examiner meant by the language in the Action of 03/16/2009 at page 6, specifically:


“With regard to alleged superior effects on inhibiting the thrombus formation and improving the hypercoagulable state, the alleged superior effect is not claimed as a range or by functional language, so Applicant’s possible unexpected result is not commensurate with the scope of the claimed invention.”

The Examiner spoke with her supervisor and stated that the language in the Action at page 6, lines 10-14 as a whole was meant to suggest to Applicants that they file a DECLARATION establishing unexpected results.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Peter D. Olexy", is written over a horizontal line.

Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 16, 2009